PARP inhibitors, genetic testing, and novel combinations

Two themes dominated the ovarian cancer headlines in 2019 — moving PARP inhibitors into earlier lines of therapy for advanced-stage disease and genetic testing.

PARP Inhibitors Take Center Stage at ESMO

At the recent European Society for Medical Oncology (ESMO) meeting, two studies showed the advantage of PARP inhibitors in newly diagnosed advanced ovarian cancer.


Image by therapractice from Pixabay

Read more…